Active monitoring for small kidney tumors
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether closely monitoring small kidney tumors (less than 4 cm) with regular imaging is a safe and effective option for people who cannot or choose not to have immediate treatment. It involves a biopsy at the start to confirm the tumor type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a small kidney tumor (less than 4 cm) found by chance on a scan
- A biopsy has confirmed the tumor is kidney cancer (any type)
- You are not able to have active treatment due to age, other health problems, or your own choice
- You are willing to have a biopsy and follow a close monitoring schedule
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether personalized monitoring of cancer DNA in your blood (MRD) can guide treatment decisions after kidney cancer surgery. If MRD is detected, you may receive extra immunotherapy to reduce the risk of cancer returning.
This study tests whether a special PET scan (using a radioactive tracer called rubidium-82) can help doctors better understand how aggressive a kidney cancer is before surgery. If you have a medium-sized kidney tumor that looks like clear cell cancer and you are scheduled for surgery, you may be able to join.
This study follows people with small, solid kidney tumors using active surveillance (regular monitoring) rather than immediate surgery or treatment. It may help you understand whether careful watching is a safe option for certain early kidney tumors.
This study tracks patients with early-stage kidney cancer (T1a, tumors smaller than 4 cm) who are treated with radiofrequency ablation, a procedure that uses heat to destroy cancer cells. It aims to see how well this treatment works in real-world practice and is only for people whose care team has already recommended this procedure.
This registry follows people who have a small kidney mass found by chance on recent scans. It helps doctors understand the best timing for monitoring and possible treatment, to improve safety and outcomes.
This trial compares two approaches for people with slow-growing, metastatic clear cell kidney cancer: taking a daily pill (belzutifan) or monitoring the cancer closely without treatment. The goal is to see if starting treatment early can help control the cancer longer than waiting.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.